Market Access News | pharmaphorum

News

The FDA has started a priority review of Otsuka's triple-acting drug for ADHD, setting up a decision on the first-in-class drug in July.

News

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus.

News

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

News

Guidance in the UK has cleared the way for NHS use of digital health technologies for people with osteoarthritis and eating disorder bulimia.

News

Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.